PURPOSE: To evaluate long-term survivors of high-grade non-Hodgkin's lymphomas (NHLs) for late effects and to attempt to assess the relative contributions of the primary treatment modalities to these late effects. PATIENTS AND METHODS: Of 103 young survivors followed up for 1 to 20 years, 74 patients were interviewed and underwent various investigations, and an additional 12 patients were interviewed only. Of the 86 patients, 65 had previously suffered from small non-cleaved-cell lymphoma, 16 from lymphoblastic lymphoma, and five from large-cell lymphoma. RESULTS: Left ventricular dysfunction was identified in eight of 57 (14.0%) patients who had received doxorubicin (DOX) in doses greater than 200 mg/m2, of whom four were symptomatic and four were asymptomatic. A ninth patient required a pacemaker. Of the 86 patients, 23 (26.7%) reported pregnancies, 18 of whom had 30 children. Two of the 86 (2.3%) patients developed second cancers. Other major late effects included posttransfusion viral hepatitis, eight patients; CNS toxicity, two patients; endocrine impairment, 14 patients; vitamin B12 deficiency, two patients; esophageal stricture, one patient; urinary tract problems, two patients; and musculoskeletal defects, three patients. Major late effects occurred in 11 of 21 (52.4%) patients who had received radiation as well as chemotherapy, eight of 22 (36.4%) patients who had surgical resections as well as chemotherapy, and 17 of 74 (23.0%) patients who had received chemotherapy alone. CONCLUSION: The predominant major late effects observed were late cardiac toxicity related to DOX therapy and hepatitis C virus infection that presumably resulted from blood product transfusions administered before the introduction of screening for the hepatitis C virus. Fertility was not greatly impaired, and second malignancies were uncommon. No patient had clinically significant impairment of growth. Radiation appeared to increase the likelihood of late effects.
PURPOSE: To evaluate long-term survivors of high-grade non-Hodgkin's lymphomas (NHLs) for late effects and to attempt to assess the relative contributions of the primary treatment modalities to these late effects. PATIENTS AND METHODS: Of 103 young survivors followed up for 1 to 20 years, 74 patients were interviewed and underwent various investigations, and an additional 12 patients were interviewed only. Of the 86 patients, 65 had previously suffered from small non-cleaved-cell lymphoma, 16 from lymphoblastic lymphoma, and five from large-cell lymphoma. RESULTS:Left ventricular dysfunction was identified in eight of 57 (14.0%) patients who had received doxorubicin (DOX) in doses greater than 200 mg/m2, of whom four were symptomatic and four were asymptomatic. A ninth patient required a pacemaker. Of the 86 patients, 23 (26.7%) reported pregnancies, 18 of whom had 30 children. Two of the 86 (2.3%) patients developed second cancers. Other major late effects included posttransfusion viral hepatitis, eight patients; CNS toxicity, two patients; endocrine impairment, 14 patients; vitamin B12 deficiency, two patients; esophageal stricture, one patient; urinary tract problems, two patients; and musculoskeletal defects, three patients. Major late effects occurred in 11 of 21 (52.4%) patients who had received radiation as well as chemotherapy, eight of 22 (36.4%) patients who had surgical resections as well as chemotherapy, and 17 of 74 (23.0%) patients who had received chemotherapy alone. CONCLUSION: The predominant major late effects observed were late cardiac toxicity related to DOX therapy and hepatitis C virus infection that presumably resulted from blood product transfusions administered before the introduction of screening for the hepatitis C virus. Fertility was not greatly impaired, and second malignancies were uncommon. No patient had clinically significant impairment of growth. Radiation appeared to increase the likelihood of late effects.
Authors: P Schütt; K Zimmermann; C Derks; P Ebeling; A Welt; M Poser; J Hense; K Metz; J Anhuf; M Sandmann; M Neise; T Moritz; M Stuschke; N Niederle; S Seeber; Mohammad R Nowrousian Journal: J Cancer Res Clin Oncol Date: 2008-08-29 Impact factor: 4.553
Authors: A Tragiannidis; Ch Dokos; V Sidi; Th Papageorgiou; D Koliouskas; M Karamouzis; Ch Papastergiou; I Tsitouridis; G Katzos; I Rousso; F Athanassiadou-Piperopoulou Journal: Hippokratia Date: 2011-01 Impact factor: 0.471
Authors: Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen Journal: Cochrane Database Syst Rev Date: 2019-04-15
Authors: Kah Poh Loh; Eric M McLaughlin; Jessica L Krok-Schoen; Oreofe O Odejide; Areej El-Jawahri; Lihong Qi; Aladdin H Shadyab; Lisa G Johnson; Electra D Paskett Journal: J Cancer Surviv Date: 2022-08-18 Impact factor: 4.062
Authors: Jong Gwang Kim; Sang Kyun Sohn; Dong Hwan Kim; Jin Ho Baek; Tae In Park; Kyu Bo Lee Journal: J Korean Med Sci Date: 2004-12 Impact factor: 2.153
Authors: Elizabeth C Bluhm; Cécile Ronckers; Robert J Hayashi; Joseph P Neglia; Ann C Mertens; Marilyn Stovall; Anna T Meadows; Pauline A Mitby; John A Whitton; Sue Hammond; Joseph D Barker; Sarah S Donaldson; Leslie L Robison; Peter D Inskip Journal: Blood Date: 2008-02-07 Impact factor: 22.113
Authors: Lonneke van de Poll-Franse; Simone Oerlemans; Anne Bredart; Charalampia Kyriakou; Monika Sztankay; Stephan Pallua; Laurien Daniëls; Carien L Creutzberg; Kim Cocks; Sandra Malak; Giovanni Caocci; Stefano Molica; Weichu Chie; Fabio Efficace Journal: Qual Life Res Date: 2017-11-10 Impact factor: 4.147
Authors: Renata Abrahão; Qian W Li; Marcio H Malogolowkin; Elysia M Alvarez; Raul C Ribeiro; Ted Wun; Theresa H M Keegan Journal: Br J Haematol Date: 2020-02-20 Impact factor: 8.615
Authors: Tanaya Shree; Qian Li; Sally L Glaser; Ann Brunson; Holden T Maecker; Robert W Haile; Ronald Levy; Theresa H M Keegan Journal: J Clin Oncol Date: 2020-02-21 Impact factor: 50.717